Trusted Resources: Education
Scientific literature and patient education texts
AA Amyloidosis: Pathogenesis and Targeted Therapy
source: Annual Review of Pathology
year: 2015
authors: Westermark GT, Fändrich M, Westermark P
summary/abstract:The understanding of why and how proteins misfold and aggregate into amyloid fibrils has increased considerably during recent years. Central to amyloid formation is an increase in the frequency of the β-sheet structure, leading to hydrogen bonding between misfolded monomers and creating a fibril that is comparably resistant to degradation. Generation of amyloid fibrils is nucleation dependent, and once formed, fibrils recruit and catalyze the conversion of native molecules. In AA amyloidosis, the expression of cytokines, particularly interleukin 6, leads to overproduction of serum amyloid A (SAA) by the liver.
A chronically high plasma concentration of SAA results in the aggregation of amyloid into cross-β-sheet fibrillar deposits by mechanisms not fully understood. Therefore, AA amyloidosis can be thought of as a consequence of long-standing inflammatory disease. This review summarizes current knowledge about AA amyloidosis. The systemic amyloidoses have been regarded as intractable conditions, but improvements in the understanding of fibril composition and pathogenesis over the past decade have led to the development of a number of different therapeutic approaches with promising results.
organization: Uppsala University, Sweden; Ulm University, GermanyDOI: 10.1146/annurev-pathol-020712-163913
read more
Related Content
-
At Least Partial Hematological Response After First Cycle of Treatment Predicts Organ Response and Long-term Surviva...AL amyloidosis is a rare plasma cell dys...
-
A Prospective Phase 2 Trial of Daratumumab in Patients With Previously Treated Systemic Light-Chain AmyloidosisDaratumumab is a human monoclonal anti...
-
Plasma Cell Antibodies – ASG Webinar 6/13https://www.youtube.com/watch?v=4gUXPbOk...
-
Introduction & Discussion: Andromeda Drug Trial (daratumumab) and Related Topicshttps://www.youtube.com/watch?v=PYbsAmtZ...
-
CyBorD With Daratumamab: Dr. Michael Rosenzweig – ASG Webinar 1/13https://www.youtube.com/watch?v=NrEjyVeJ...
-
Daratumumab-Based Therapies in Patients With AL AmyloidosisBackground: Treatment options for patie...
-
Immunomodulatory Imide Drugs (IMiDs) – ASG Webinar 7/13https://www.youtube.com/watch?v=4gUXPbOk...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.